FATP2介导的脂代谢增强B-ALL CAR-T治疗抵抗
研究在B-ALL细胞系和患者来源异种移植模型中探索CAR-T抵抗机制,发现p53失活通过FATP2(SLC27A2)介导的外源脂质摄取和脂肪酸氧化促进抵抗,靶向该通路可改善CAR-T疗效。
要点
- p53失活促进B-ALL对CD19 CAR-T治疗抵抗
- FATP2高表达与儿童B-ALL常规化疗后生存较差相关
- 抑制中性脂解或CPT1可逆转FATP2介导的CAR-T抵抗
核心结论
- FATP2介导的脂肪酸摄取及下游脂肪酸氧化是TP53突变B-ALL对CAR-T抵抗的机制,可作为改善CAR-T疗效的潜在靶点。
研究设计与样本
- 研究使用人pre-B-ALL细胞系和患者来源异种移植(PDX)模型。
- 对CAR敏感TP53野生型和CAR抵抗TP53突变CD19+ B-ALL细胞系进行全基因组CRISPR/Cas9筛选。
主要发现
- p53失活促进人pre-B-ALL细胞系对CAR-T抵抗。
- 全基因组CRISPR/Cas9筛选发现FATP2(由SLC27A2编码)是TP53突变B-ALL中白血病内在的CAR-T抵抗机制。
- 儿童B-ALL患者中SLC27A2高表达与常规化疗后生存结局较差相关。
- 表达FATP2的TP53突变B-ALL对CAR-T抵抗依赖于外源脂质摄取以供给脂肪酸氧化(FAO)和细胞存活。
临床怎么用
- 可考虑药理学抑制中性脂解和CPT1来靶向FATP2介导的脂质摄取和FAO,以改善B-ALL CAR-T疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) remains a leading cause of cancer-related death in children and young adults. While CD19-directed chimeric antigen receptor T cell (CAR-T) therapy offers promise, high rates of long-term failure underscore the need to understand resistance mechanisms. Our studies found p53 inactivation promotes CAR-T resistance in human pre-B-ALL cell lines. Through genome-wide CRISPR/Cas9 screening of CAR-sensitive TP53-wildtype and CAR-resistant TP53-mutated CD19 + B-ALL cell lines, we found the Fatty Acid Transport Protein 2 (FATP2, encoded by SLC27A2) is a leukemia-intrinsic mechanism of CAR-T resistance in TP53-mutant B-ALL. High SLC27A2 expression in pediatric B-ALL patients correlate with worse survival outcomes following conventional chemotherapy. Using B-ALL cell lines and patient-derived xenografts, we show that FATP2-expressing TP53-mutant B-ALL resistance to CAR-T is dependent on exogenous lipid uptake to fuel fatty acid oxidation (FAO) and cell survival, which can be pharmacologically targeted through inhibition of neutral lipolysis and CPT1. These findings identify FATP2-mediated fatty acid uptake and downstream FAO as a potential target to improve existing CAR-T efficacy in human B-ALL.
引用
- Garcia C, Lyons KU, Contreras JG, et al. FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia. Leukemia. 2026. PMID: 42380664. doi:10.1038/s41375-026-03030-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。